Enzyme-linked immunosorbent assay for leucine and methionine enkephalins

An immunoassay for Leu-enkephalin based on a C-terminal aequorin-peptide fusion

Recently we demonstrated that the fusion of an octapeptide to the C-terminus of a cysteine-free mutant of aequorin showed no inhibitory effect on the luminescence activity of the photoprotein. This observation is of particular importance when the use of aequorin as a label in the development of immunoassays for peptides whose activity lies in their C-terminal region or the epitope for antibody recognition is at their C-terminus is desired. In the case of opioid peptides, antibodies are directed toward their C-terminus as they differ from each other at this terminus. The goal of this study was to develop an immunoassay for Leu-enkephalin, a mammalian opioid peptide, using a C-terminal aequorin-peptide fusion protein. For that, the N-terminus of Leu-enkephalin was genetically fused to the C-terminus of a cysteine-free mutant of aequorin. It was observed that the C-terminal conjugated aequorin maintained its luminescence activity. An immunoassay for Leu-enkephalin was then developed using the aequorin-Leu-enkephalin fusion protein as a labeled analyte in a competitive as well as in a sequential binding mode. It was demonstrated that aequorin can be used as a label in peptide assays in which it is critical that the peptide's C-terminus be free for activity and/or for antibody recognition.

A sensitive and specific enzyme-linked immunosorbent assay for methionine enkephalin sulphoxide

An enzyme-linked immunosorbent assay (ELISA) for the sulphoxide derivative of the opioid peptide methionine enkephalin (MOE) was developed and found to be sensitive and highly specific. Methionine enkephalin itself showed only low cross-reactivity (1.8%) in the assay while leucine enkephalin and the endorphins showed cross-reactivity no higher than 0.6%. Given the ease of application, low cost and stable nature of the label, this technique is a useful alternative to existing radioimmunoassays for the peptide.

Basal level of prostaglandin D2 in rat brain by a solid-phase enzyme immunoassay

A solid-phase enzyme immunoassay for prostaglandin D2 (PGD2) was developed in which PGD2 was labeled with horseradish peroxidase. After competitive binding to the immobilized antibody between enzyme-labeled and free PGD2, the activity of the enzyme bound to the antibody was assayed fluorometrically using 3-(p-hydroxyphenyl)-propionic acid and hydrogen peroxide as substrates. The procedure allowed determinations of 3-100 pg for PGD2. The IC50 value for PGD2 in the solid-phase enzyme immunoassay was about 25 pg and the sensitivity was improved about 10 times compared to those in radioimmunoassay and in solution-phase enzyme immunoassay. The solid-phase enzyme immunoassay was applied to the measurement of PGD2 content in rat brain and thereby an octadecylsilyl silica cartridge and a reversed-phase HPLC were sequentially used for sample preparations. Heads were immediately frozen in liquid nitrogen after decapitation to avoid a postmortem formation of PGD2. PGD2 contents measured by solid-phase enzyme immunoassay correlated well with the values obtained by radioimmunoassay (r = 0.966) after raising its contents by intravenous administration of PGD2. The in vivo level of PGD2 in rat brain was extremely low but determined to be 0.11 +/- 0.03 ng/g tissue (mean +/- S.E.M.) with this enzyme immunoassay. The result was equal to the value extrapolated to zero time from the postmortem change.

Enteric nerves in diabetic rats: increase in vasoactive intestinal polypeptide but not substance P

The distribution of vasoactive intestinal polypeptide (VIP) and substance P-like immunoreactivities was studied by immunohistochemistry in the myenteric plexus and circular muscle layer of the ileum and proximal colon of rats 8 wk after induction of diabetes with streptozotocin. A consistent increase was observed in fluorescence intensity of VIP-like immunoreactivity in the nerve fibers, and intensely stained cell bodies were significantly more frequent in the myenteric plexus of the ileum (p less than 0.001) from diabetic animals. Some varicosities of VIP-like immunoreactive fibers in the myenteric plexus appeared to be enlarged. Vasoactive intestinal polypeptide-like immunoreactivity was increased and VIP-like immunoreactive nerves appeared thicker in the circular muscle layer of both diabetic ileum and proximal colon. The VIP levels were measured biochemically in tissue consisting of the smooth muscle layers and myenteric plexus. A significant increase in the VIP content per centimeter of intestine was found in both the ileum (p less than and proximal colon (p less than 0.01) from diabetic rats. In contrast, no apparent change in substance P innervation was observed immunohistochemically in the myenteric plexus and circular muscle layer of either diabetic ileum or proximal colon when compared with controls. The results are discussed in relation to the symptoms of autonomic neuropathy of the gut in diabetes.

Enzyme-linked immunosorbent assay of substance P and its metabolite SP 1-7. A comparison with RIA

We have investigated enzyme-linked immunosorbent assay (ELISA) as a possible alternative to radioimmunoassay (RIA) for the detection and measurement of the neuropeptide substance P (SP) and its metabolite substance P1-7. The sensitivities were higher with ELISA than with RIA utilizing the same antisera. The intra-assay and inter-assay variation in ELISA was 1% and 13% respectively. The higher sensitivities are in part due to the standard curves having less steep slopes, and in part to lower IC50s in the ELISA. Since there was a good correlation between peptide levels in biological samples as determined by ELISA and RIA respectively, ELISA might be considered an attractive alternative to RIA.

Enzyme-linked immunosorbent assay for Met-enkephalin using unconjugated enkephalin as a solid phase antigen

This paper presents a competitive enzyme-linked immunosorbent assay for Met-enkephalin, in which there is no need for preparing any special derivative of Met-enkephalin for its optimal function as a solid-phase antigen. Immunoplate wells were first coated with free Met-enkephalin, and then incubated with antiserum and free Met-enkephalin. The antibodies bound to the solid-phase Met-enkephalin were determined by using anti-IgG conjugated to horseradish peroxidase. The detection limit of the assay was 44 fmol Met-enkephalin per well. The results also showed that Met-enkephalin bound to the solid phase can be titrated directly.

Enzyme-linked immunosorbent assay for the neuropeptide 'head activator'

By exposing different sites of the 'head activator', different sets of antibodies were designed and produced which recognised either the amino or the carboxy terminus of the free 'head activator', which reacted with 'head activator' in a tissue-fixed conformation, or which bound to the 'head-activator' sequence, if it was part of a larger precursor-like molecule. An enzyme-linked immunosorbent assay (ELISA) was developed to characterise the antibodies and also to assay minute amounts of 'head activator' or 'head-activator'-like immunoreactivities in animal or tissue extracts. A competitive ELISA is described which uses biotin-avidin for enhancement. The assay is sensitive with an antibody specific for the amino terminus in the range of 0.5-50 fmol, with an antibody specific for the carboxy terminus in the range of 20-400 fmol. The ELISA specific for the amino terminus is 10-times more sensitive than a radio-immunoassay with tritiated 'head activator' [H. Bodenmüller and B. Zachmann (1983) FEBS Lett. 159,237-240]. Previously no radioimmunoassay existed with specificity for the carboxy terminus.